PR86733

SAN FRANCISCO and ANN ARBOR, Mich., Nov. 19, 2020 /PRNewswire=KYODO JBN/ --

endpoint Clinical (https://c212.net/c/link/?t=0&l=en&o=2986884-1&h=3561717008&u=https%3A%2F%2Fwww.endpointclinical.com%2Firt-solution%2F&a=endpoint+Clinical ), the leading global interactive response

technology (IRT(R)) company, and McCreadie Group (https://c212.net/c/link/?t=0&l=en&o=2986884-1&h=189926791&u=https%3A%2F%2Fwww.mccreadiegroup.com%2Fsolutions%2Fvestigo%2F&a=McCreadie+Group ), the market leader in automating manual processes

in Investigational Drug Services (IDS), have collaborated to increase study

product accountability transparency for study sponsors, reduce site burdens

associated with clinical study IMP management, and improve related data

integrity via carefully balanced interfacing of McCreadie's site-based Vestigo(R)

application and endpoint's PULSE(R) IRT.

The collaboration will leverage the unique investigational product

accountability features of the Vestigo site-focused software and PULSE

software's drug supply management features of IRT implementations.  

"Hearing issues raised by sponsors regarding the disposition of the study

product and having an understanding of the valuable data Vestigo(R) provides,

we knew there was a unique opportunity to partner together," said Ryan Keane

(https://c212.net/c/link/?t=0&l=en&o=2986884-1&h=4294249089&u=https%3A%2F%2Fwww.linkedin.com%2Fin%2Fryan-keane-2293ba1%2F&a=Ryan+Keane ), CCO, endpoint. "The convenience that sites

gain by reduced training and time savings associated with avoidance of logging

transactions in multiple applications is an obvious win-win situation."

The powerful combination of Vestigo and PULSE, when integrated, will deliver

significant benefits to sponsors alongside an exceptional site experience.

Sponsors will benefit through improved data integrity consistent in format,

lowered risk of protocol deviations due to data validation checks, access to

site inventory levels, and visibility of IP disposition, including return and

destruction information. All these benefits help to achieve faster data

closeout. Site pharmacy teams will gain efficiency by eliminating the need to

access multiple systems to document drug receipt, dispensing, and final

disposition. All the data entered by site pharmacists will be automatically

populated via the integration.  

"Having managed busy research pharmacy sites for several years before joining

McCreadie, I can attest that the integration of Vestigo and PULSE will improve

the efficiency of IDS operations," says Richard Malone (https://c212.net/c/link/?t=0&l=en&o=2986884-1&h=2993562097&u=https%3A%2F%2Fwww.linkedin.com%2Fin%2Frichard-malone-893221178%2F&a=Richard+Malone ), Business Development Executive

at McCreadie Group. "Elimination of duplicate work and streamlining daily functions

such as the receipt of shipments and documentation of IMP dispensing, returns,

destruction, and other status changes allows IDS staff members to shift focus to

other duties. Equally as significant is the resulting improvement in integrity and

timeliness of data that should benefit all parties involved, including sponsors

(and their partners), monitors, site personnel, and patients."

It is widely recognized that the traditional models of system interaction rely

too heavily upon site staff, serving as almost a physical point of integration,

and are rapidly becoming outmoded. This new approach of directly interfacing

site-owned software with the sponsor and CRO provisioned solutions like IRT

represents an exciting new dimension to help drive best practices across the board.  

About McCreadie  

The McCreadie Group, Inc. was founded in 2004 to provide software solutions for

pharmacy applications in healthcare, research, and educational settings.

McCreadie Group's goal is to drive improvements in quality, efficiency, safety,

and compliance in the pharmacy profession by delivering innovative software and

consultative support. To learn more about McCreadie Group and its products,

visit www.mccreadiegroup.com.

About endpoint

endpoint is an interactive response technology (IRT(R)) systems and solutions

provider that supports the life sciences industry.  For the past decade, their

customer-obsessed team of professionals has been continuously evolving their

suite of technologies to help Sponsors achieve clinical trial success.  Their

dynamic IRT solution, PULSE (R), for patient randomization and management, site

management, and drug supply management and leading-edge clinical supplies

management tool, DRIVE, has proven to maximize the supply chain and minimize

operational costs, and ensure timely and accurate patient dosing. endpoint is

headquartered in San Francisco, California, with offices across the US, EU, and

Asia. www.endpointclinical.com

Contacts:

Catherine Ditzler

Associate Director of Marketing

endpoint Clinical

+1-415-688-3424

e: cditzler@endpointclinical.com

Jennifer Drabing

Senior Marketing Communications Manager

McCreadie Group

+1 (734) 661-7955

e: jennifer@mccreadiegroup.com

SOURCE: endpoint Clinical